ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting

Rhea-AI Summary

ProMIS Neurosciences, a biotechnology firm focused on therapeutics for neurodegenerative diseases, presented research at the American Academy of Neurology Annual Meeting (April 2-7, 2022). Dr. Beibei Zhao showcased findings on RACK1 knockdown's potential benefits against TDP-43-related pathology, suggesting a pathogenic interaction with neurodegeneration. This work underscores ProMIS's innovative approach to tackling diseases like ALS, Alzheimer's, and Parkinson's through its proprietary target discovery platform. Further details are accessible on ProMIS's website and the AAN portal.

Positive

• Presented promising research on RACK1 knockdown potentially alleviating TDP-43-related neurodegeneration.
• Demonstrated innovative therapeutic approaches targeting misfolded proteins implicated in neurodegenerative diseases.

Negative

• None.

TORONTO, Ontario and CAMBRIDGE, MA, April 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has presented at the American Academy of Neurology (AAN) Annual Meeting held at the Washington State Convention Center in Seattle, April 2-7, 2022.

Dr. Beibei Zhao delivered a poster presentation entitled: “RACK1 Knockdown Alleviates TDP-43-Associated Global Translational Suppression in vitro and Neurodegeneration in vivo” during Session P3: Neuromuscular Disease: Amyotrophic Lateral Sclerosis 3, on Saturday, April 2^nd. 

The receptor of activated C-kinase 1 (RACK1) is a well-conserved protein with more than 100 recognized activities. Co- aggregation of RACK1 with TDP-43 inclusions has been observed in sporadic ALS suggesting that it may be part of a pathogenic interactome involving the two proteins.

The poster addresses whether knockdown of RACK1 in mature cells may be beneficial against TDP-43 related pathology in cultured cells and in a living organism, the Drosophila fruit fly. The results are consistent with the existence of a pathogenic interaction between TDP-43 and RACK1 in misfolded aggregates and support targeting of RACK1 to alleviate TDP-43 proteinopathy.

The poster abstract is available on the AAN website here. Dr. Zhao’s poster presentation will be available on the ProMIS website (www.promisneurosciences.com) at the conclusion of the meeting.

For more information about the meeting please consult the AAN annual meeting website.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF

To learn more, visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###

FAQ

What was presented by ProMIS Neurosciences at the AAN Annual Meeting on April 2, 2022?

ProMIS Neurosciences presented research on RACK1 knockdown's potential to alleviate TDP-43-associated neurodegeneration.

What is the significance of RACK1 in ProMIS Neurosciences' research?

RACK1 is implicated in a pathogenic interaction with TDP-43, which is associated with neurodegenerative diseases.

Which neurodegenerative diseases does ProMIS Neurosciences focus on?

ProMIS focuses on Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease.

What is the stock symbol for ProMIS Neurosciences?

ProMIS Neurosciences is listed under the stock symbol ARFXF on the OTCQB Venture Market.